Defunct Company
Total Trials
11
As Lead Sponsor
9
As Collaborator
2
Total Enrollment
682
NCT00004408
Phase III Randomized Study of Poloxamer 188 for Vaso-Occlusive Crisis of Sickle Cell Disease
Phase: Phase 3
Role: Collaborator
Start: Nov 30, 1997
Completion: Nov 30, 1999
NCT00244244
A Multicenter, Dose Ranging Safety and Pharmacokinetics Study of Arimoclomol in ALS
Phase: Phase 2
Role: Lead Sponsor
Start: Oct 31, 2005
Completion: Jan 31, 2007
NCT00352677
Safety and Tolerability Study of INNO-406 to Treat Chronic Myeloid Leukemia or Acute Lymphocytic Leukemia
Phase: Phase 1
Start: Jul 31, 2006
Completion: May 31, 2008
NCT00520208
Safety, Efficacy, & Pharmacokinetic Study of Tamibarotene to Treat Patients With Relapsed or Refractory APL
Start: Sep 30, 2007
Completion: Jan 31, 2013
NCT00472771
INNO-206 in Patients With Small Cell Lung Cancer (SCLC)
Start: May 31, 2008
Completion: Nov 30, 2008
NCT00985530
Tamibarotene and Arsenic Trioxide for Relapsed Acute Promyelocytic Leukemia
Start: Oct 31, 2009
Completion: May 31, 2011
NCT01144260
Study of Bafetinib as Treatment for Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL)
Start: Jun 30, 2010
Completion: Apr 30, 2013
NCT01215799
Study of Bafetinib (INNO-406) as Treatment for Patients With Hormone-Refractory Prostate Cancer
Start: Aug 31, 2010
Completion: Dec 31, 2011
NCT01337154
First Line Study of Tamibarotene in Combination for Advanced Non-Small Cell Lung Cancer
Start: Apr 30, 2011
Completion: Jun 30, 2013